Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model (Q48287471)

10 February 2018

title

Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model (English)

1 reference

10 February 2018

0 references

1 reference

1 reference

Sung-Dong Park

1 reference

10 February 2018

Chang-Hyun Kim

1 reference

10 February 2018

Chung-Kwon Kim

1 reference

10 February 2018

Jin-A Park

1 reference

10 February 2018

Hyun-Jung Sohn

1 reference

10 February 2018

Yong-Kil Hong

1 reference

10 February 2018

Tai-Gyu Kim

1 reference

10 February 2018

language of work or name

English

0 references

publication date

17 January 2007

1 reference

10 February 2018

published in

Vaccine

1 reference

10 February 2018

volume

1 reference

10 February 2018

issue

1 reference

10 February 2018

page(s)

3485-3491

1 reference

10 February 2018

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Dendritic cells in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Dendritic cells: immunobiology and cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Quantitatively determined survivin expression levels are of prognostic value in human gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Survivin, versatile modulation of cell division and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Survivin, a cancer target with an emerging role in normal adult tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Immunotherapy and chemotherapy--a practical partnership

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Regulatory T cells, tumour immunity and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.060

10.1016/J.VACCINE.2006.12.060

7 January 2021

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018